IL6 and systemic sclerosis: This point is important, for example, since although an anti–IL-6 antibody was recently found not to affect skin fibrosis in SSc patients (Khanna et al. 2020), such a treatment was recently shown to improve periodontal outcomes in patients with rheumatoid arthritis (Ancut,a et al. 2021).